Terms: = Endocrine gland cancer AND AKT2, PKBBETA, 208, ENSG00000105221, RAC-BETA, P31751, PRKBB AND Clinical Outcome
4 results:
1. Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy.
Feng H; Qiu L; Shi Z; Sheng Y; Zhao P; Zhou D; Li F; Yu H; You Y; Wang H; Li M; Zhu S; Du Y; Cui J; Sun J; Liu Y; Jiang H; Wu X
Cancer Med; 2023 Feb; 12(3):3313-3327. PubMed ID: 36028997
[TBL] [Abstract] [Full Text] [Related]
2. CTLA-4 polymorphism contributes to the genetic susceptibility of epithelial ovarian cancer.
Chen J; Kang S; Wu J; Zhao J; Si W; Sun H; Li Y
J Obstet Gynaecol Res; 2022 May; 48(5):1240-1247. PubMed ID: 35150042
[TBL] [Abstract] [Full Text] [Related]
3. Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis.
Wong KS; Higgins SE; Marqusee E; Nehs MA; Angell T; Barletta JA
Endocr Pathol; 2019 Mar; 30(1):43-48. PubMed ID: 30565013
[TBL] [Abstract] [Full Text] [Related]
4. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract] [Full Text] [Related]
